Resume-aware faculty matching

Find professors who actually fit you

Upload your resume. Four AI agents analyze your background, rank the faculty who fit, inspect their recent research, and help you draft outreach — grounded in their actual work, not templates.

Free to startNo credit cardCancel anytime
Top matches Balanced preset
Dr. Sarah Chen
Stanford · Interpretability · NLP
91
Dr. Marcus Holloway
MIT · Robotics · RL
84
Dr. Aisha Okonkwo
CMU · Fairness · HCI
82
Nova · Professor Researcher · re-ranking top 20…

Jonathan Dranoff

· Professor of Medicine (Digestive Diseases); Director, Steatotic Liver Disease Program , Digestive Diseases, VA Connecticut Healthcare System

Yale University · Gastroenterology

Active 1998–2024

h-index31
Citations3.9k
Papers13038 last 5y
Funding$4.9M
See your match with Jonathan Dranoff — sign in to PhdFit.Sign in

About

Jonathan Dranoff, MD, is a professor of medicine in the Section of Digestive Diseases at Yale School of Medicine. He is also the director of the Steatotic Liver Disease Program at the VA Connecticut Healthcare System. Dr. Dranoff is a physician and scholar with expertise in liver disease pathophysiology, focusing on areas such as drug-induced liver injury, including acetaminophen safety and toxicity in patients with advanced chronic liver disease. His research interests include exploring the effects of exercise and coffee consumption on steatotic liver disease, as well as investigating liver fibrosis, cirrhosis, non-alcoholic fatty liver disease, and the safety and efficacy of various treatments. His work involves population-based studies and clinical research aimed at understanding and managing liver conditions, particularly in relation to metabolic dysfunction, lean liver disease, and advanced fibrosis.

Research topics

  • Internal medicine
  • Gastroenterology
  • Medicine
  • Intensive care medicine
  • Biology
  • Endocrinology
  • General surgery
  • Biochemistry
  • Pharmacology
  • Pathology

Selected publications

  • AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis

    Hepatology · 2024 · 141 citations

    • Medicine
    • Internal medicine
    • Gastroenterology

    Sterling, Richard K.; Duarte-Rojo, Andres; Patel, Keyur; Asrani, Sumeet K.; Alsawas, Mouaz; Dranoff, Jonathan A.; Fiel, Maria Isabel; Murad, M. Hassan; Leung, Daniel H.; Levine, Deborah; Taddei, Tamar H.; Taouli, Bachir; Rockey, Don C. Author Information

  • Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

    Digestive Diseases and Sciences · 2022 · 63 citations

    • Medicine
    • Internal medicine
    • Gastroenterology
  • Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways

    Toxicological Sciences · 2022 · 36 citations

    • Medicine
    • Internal medicine
    • Gastroenterology

    Better biomarkers to predict death early in acute liver failure (ALF) are needed. To that end, we obtained early (study day 1) and later (day 3) serum samples from transplant-free survivors (n = 28) and nonsurvivors (n = 30) of acetaminophen-induced ALF from the NIH-sponsored Acute Liver Failure Study Group and from control volunteers (n = 10). To identify proteins that increase early in serum during ALF, we selected individuals from this cohort for whom alanine aminotransferase was lower on day 1 than day 3, indicating a time point before peak injury (n = 10/group). We then performed untargeted proteomics on their day 1 samples. Out of 1682 quantifiable proteins, 361 were ≥ 4-fold elevated or decreased in ALF patients versus controls and 16 of those were further elevated or decreased ≥ 4-fold in nonsurvivors versus survivors, indicating potential to predict death. Interestingly, 1 of the biomarkers was lactate dehydrogenase (LDH), which is already measured in most clinical laboratories. To validate our proteomics results and to confirm the prognostic potential of LDH, we measured LDH activity in all day 1 and 3 samples from all 58 ALF patients. LDH was elevated in the nonsurvivors versus survivors on both days. In addition, it had prognostic value similar to the model for end-stage liver disease and outperformed the King's College Criteria, while a combination of model for end-stage liver disease and LDH together outperformed either alone. Finally, bioinformatics analysis of our proteomics data revealed alteration of numerous signaling pathways that may be important in liver regeneration. Overall, we conclude LDH can predict death in APAP-induced ALF.

Recent grants

Frequent coauthors

  • Michel Fausther

    University of Arkansas for Medical Sciences

    74 shared
  • Élise G. Lavoie

    Université Laval

    44 shared
  • Emir Tas

    Arkansas Children's Hospital

    26 shared
  • Nina Sheung

    Milford Elementary School

    25 shared
  • Eva C. Diaz

    University of Arkansas for Medical Sciences

    24 shared
  • Jean Sévigny

    Hudson Institute of Medical Research

    24 shared
  • Gianfranco Alpini

    Richard L. Roudebush VA Medical Center

    24 shared
  • Jesús M. Bañales

    22 shared

Similar researchers at Yale University

  • Resume-aware match score
  • Save to shortlist
  • AI-drafted outreach

See your match with Jonathan Dranoff

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

  • Free to start
  • No credit card
  • 30-second signup